KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Gross Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported Gross Margin over the past 17 years, most recently at 91.8% for Q4 2025.

  • Quarterly results put Gross Margin at 91.8% for Q4 2025, up 42.0% from a year ago — trailing twelve months through Dec 2025 was 92.47% (down 12.0% YoY), and the annual figure for FY2025 was 92.05%, down 30.0%.
  • Gross Margin for Q4 2025 was 91.8% at Regeneron Pharmaceuticals, down from 93.59% in the prior quarter.
  • Over the last five years, Gross Margin for REGN hit a ceiling of 97.0% in Q2 2021 and a floor of 364.92% in Q4 2022.
  • Median Gross Margin over the past 5 years was 92.85% (2021), compared with a mean of 43.06%.
  • Biggest five-year swings in Gross Margin: crashed -40736bps in 2022 and later skyrocketed 45599bps in 2023.
  • Regeneron Pharmaceuticals' Gross Margin stood at 42.42% in 2021, then crashed by -760bps to 364.92% in 2022, then skyrocketed by 125bps to 91.07% in 2023, then grew by 0bps to 91.38% in 2024, then rose by 0bps to 91.8% in 2025.
  • The last three reported values for Gross Margin were 91.8% (Q4 2025), 93.59% (Q3 2025), and 93.07% (Q2 2025) per Business Quant data.